Pre­sent­ing a live End­points News event: Man­ag­ing a biotech in tur­bu­lent times

Biotech is one of the smartest, best ed­u­cat­ed in­dus­tries on the plan­et. PhDs abound. We’ve had a long enough track record to see a new gen­er­a­tion of savvy, ex­pe­ri­enced ex­ecs com­ing to­geth­er to run star­tups.

And in these times, they are be­ing test­ed as nev­er be­fore.

Biotech is go­ing through quite a rough patch right now. For 2 years, prac­ti­cal­ly any­one with a de­cent re­sume and some half-baked ideas on biotech could start a com­pa­ny and get it fund­ed. The pan­dem­ic made it easy in many ways to pull off an IPO, with tra­di­tion­al road shows shut down in ex­change for a se­ries of quick Zoom meet­ings. Gen­er­al­ist in­vestors flocked as the num­bers raised soared in­to the stratos­phere.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE